Related Experiment Videos
Disease progression in stage A prostate cancer
Summary
Stage A prostate cancer progression primarily occurs in the A2 subgroup, indicated by higher ras p21 expression and nucleolar organizer regions. These findings highlight the proliferative potential of early-stage prostate cancer.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Prostate cancer staging is crucial for predicting disease course.
- Early-stage prostate cancer (Stage A) requires detailed study for progression patterns.
Purpose of the Study:
- To investigate disease progression in Stage A prostate cancer patients.
- To identify factors associated with progression in Stage A prostate cancer.
Main Methods:
- Retrospective follow-up of 212 Stage A prostate cancer patients (103 A1, 109 A2) who underwent prostatectomy (1972-1991).
- Analysis of progression to clinical cancer, time to progression, and response to endocrine therapy.
- Evaluation of ras p21 expression and argyrophilic nucleolar organizer regions (AgNORs) in cancer cells.
Main Results:
- Twelve patients (5.7%) progressed to clinical cancer, predominantly from the A2 subgroup (10/109).
- Progression occurred at a median of 40.5 months post-prostatectomy, with 67% responding to endocrine therapy.
- Higher ras p21 expression and AgNOR counts were observed in progressing cases compared to non-progressing cases.
Conclusions:
- Stage A prostate cancer progression mainly originates from the A2 subgroup.
- Elevated ras p21 and AgNORs indicate increased proliferative potential in progressing Stage A cancer.
- These biomarkers may aid in identifying aggressive early-stage prostate cancer.